Skip to content

Robotic Nipple-Sparing Mastectomy Vs Conventional Open Technique

Robotic Nipple-Sparing Mastectomy And Immediate Robotic Breast Reconstruction Vs Conventional Open Technique: A Prospective Randomized Trial Evaluating Patients Satisfaction

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03440398
Enrollment
82
Registered
2018-02-22
Start date
2017-03-31
Completion date
2026-02-01
Last updated
2026-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Robotic Mastectomy, Nipple Sparing Mastectomy, Conservative mastectomy, Breast reconstruction

Brief summary

This trial is designed to compare robotic nipple-sparing mastectomy and immediate robotic breast reconstruction with conventional open technique. It is a prospective randomized trial evaluating patients satisfaction

Detailed description

High proportion of patients with newly diagnosed early-stage breast cancer in Europe and US undergo to mastectomy. The absolute numbers of mastectomy rates in US is still today around 38% and represent one of the most performed operation for cancer reasons. Despite the lack of a natural cavity needed for endoscopic viewing, applications of robotic surgery have recently emerged for superficial organs such as in the fields of thyroidectomy, oropharyngeal surgery, plastic and reconstructive surgery. However, it has never been applied in breast cancer except for a feasibility and safety study conducted at European Institute of Oncology. The technique was firstly published by Toesca et al. considering the first 3 cases. The same research as continued on breast cancer evaluating feasibility, reproducibility and safety studying 26 consecutive procedures of robotic nipple sparing mastectomy and immediate robotic breast reconstruction (article under peer to peer review at European Journal of Surgical Oncology, EJSO). In these initial cases of robotic nipple sparing mastectomy and immediate breast reconstruction authors found two main advantages such as the robotic optical vision and the minimal invasiveness. The two main limitations noticed in this initial experience were the duration of operating time and the additional costs related to the operation. The limitations of the applicability of robotic surgery to the breast, such as operating time and costs, might be offset by the advantages they observed such as better vision and minimally invasive approach with an anatomically more respectful mastectomy. This project is a superiority trial comparing robotic nipple sparing mastectomy and immediate breast robotic reconstruction with conventional open technique. The primary end-point is to evaluate patient satisfaction. Second end-point is to compare post-operative outcome considering complications, post-operative pain, reduction of the average length of stay of patients, long term oncological outcome of the two different surgical techniques. Patients will be randomized into two treatment arms: A. Open nipple-sparing mastectomy and immediate breast reconstruction with implant (Open NSM) B. Robotic nipple-sparing mastectomy and immediate robotic breast reconstruction with implant (Robotic NSM) Both arms will undergo to the same pre-surgical staging, intra-operative axillary surgical staging, post-operative multidisciplinary evaluation and adjuvant treatments according to international and internal protocols.

Interventions

PROCEDURERobotic NSM

Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction

PROCEDUREOpen NSM

Open nipple-sparing mastectomy and immediate breast reconstruction with implant

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Invasive breast cancer, Ductal Carcinoma In Situ, Breast Related Cancer Antigens mutation carriers. * Any age * Candidates to nipple-sparing mastectomy and immediate breast reconstruction * Negative preoperative assessment of nipple-areola complex * Absence of skin involvement * Low probability to have positivity of nipple-areola complex tissue intra-operative frozen section * Breast volume ≤ Bra IV; from cup A to D * No hard smoking (hard smoking defined as \>20 cigarettes/day) * Low and intermediate risk for anesthesia (ASA Scale) * Written informed consent must be signed and dated by the patient and the investigator prior to inclusion * Patients must be accessible for follow-up

Exclusion criteria

* Previous thoracic radiation therapy for any reason * Inflammatory Breast Cancer * Skin involvement * Pre-operative diagnosis (radiological or cytological) of nipple-areola complex disease * Pregnancy * Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study * Uncompensated Diabetes Mellitus * Hard smokers (hard smoking defined as \>20 cigarettes/day) * High risk for anesthesia

Design outcomes

Primary

MeasureTime frameDescription
Patient satisfaction1 yearThe BREAST-Q survey is used to detect differences in patient satisfaction among the groups

Secondary

MeasureTime frameDescription
Average length of stay of patients1 monthReduction of the average length of stay of patients of the two different surgical techniques.
Post operative complications1 monthCompare post operative complications (pain, skin or nipple-areola injury or necrosis or infection, hematoma, seroma)
Cumulative incidence of local recurrence5 yearsCumulative incidence of local recurrence
Cumulative incidence of axillary recurrences5 yearsCumulative incidence of axillary recurrences
Cumulative incidence of distant recurrences5 yearsCumulative incidence of distant recurrences
Disease free survival5 yearsDisease free survival
Overall survival5 yearsOverall survival

Countries

Italy

Contacts

PRINCIPAL_INVESTIGATORPaolo Veronesi, MD

European Institute of Oncology

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 25, 2026